Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDHVK8)

Drug Name

LNA043 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Knee osteoarthritis	FA01	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Angiopoietin-related protein 3 (ANGPTL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Evinacumab	DMBLX7U	Hypercholesterolaemia	5C80.0	Approved	[3]
AKCEA-ANGPTL3-LRX	DMR8W7Y	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-related protein 3 (ANGPTL3)	TTUO98L	ANGL3_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04864392) A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis. U.S.National Institutes of Health.
2	Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat Med. 2022 Dec;28(12):2633-2645.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)